Repetitive evaluation of fibrillation cycle length predicts the efficacy of bepridil for interruption of long-lasting persistent atrial fibrillation

International Heart Journal

Volumn 52, Issue 6, 2011, Pages 353-358

  Aoyama, Yuya ^a   Niwano, Shinichi ^a   Niwano, Hiroe ^a   Satoh, Akira ^a   Kishihara, Jun ^a   Ishikawa, Shoko ^a   Murakami, Masami ^a   Fukumoto, Kyoko ^b   Ueno, Kazuyuki ^b   Izumi, Tohru ^a  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NIIGATA UNIVERSITY OF PHARMACY AND APPLIED LIFE SCIENCES   (Japan)

Author keywords

Bepridil; Fibrillation cycle length; Persistent atrial fibrillation; Spectral analysis

Indexed keywords

BEPRIDIL;

AGED; ARTICLE; CARDIOVASCULAR PARAMETERS; CARDIOVERSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; ELECTROCARDIOGRAM; FEMALE; FIBRILLATION CYCLE LENGTH; HEART ATRIUM FIBRILLATION; HEART RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QT INTERVAL; QT PROLONGATION; SIDE EFFECT; SINUS RHYTHM; TORSADE DES POINTES; TU WAVE;

AGED; ATRIAL FIBRILLATION; BEPRIDIL; CALCIUM CHANNEL BLOCKERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HEART RATE; HUMANS; MALE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84255205466     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.52.353     Document Type: Article

References (26)

1. 2+-dependent action potentials in vascular muscle of dog coronary artery. J Car-diovasc Pharmacol 1981; 3: 906-14.
2. DiBianco R, Alpert J, Katz RJ, et al. Bepridil for chronic stable angina pectoris: results of a prospective multicenter, placebo-con-trolled, dose-ranging study in 77 patients. Am J Cardiol 1984; 53: 35-41.
3. Fujiki A, Tsuneda T, Sugao M, Mizumaki K, Inoue H. Usefulness and safety of bepridil in converting persistent atrial fibrillation to sinus rhythm. Am J Cardiol 2003; 92: 472-5.
4. Nakazato Y, Yasuda M, Sasaki A, et al. Conversion and mainte-nance of sinus rhythm by bepridil in patients with persistent atrial fibrillation. Circ J 2005; 69: 44-8.
5. Yatani A, Brown AM, Schwartz A. Bepridil block of cardiac calci-um and sodium channels. J Pharmacol Exp Ther 1986; 237: 9-17.
6. Wang JC, Kiyosue T, Kiriyama K, Arita M. Bepridil differentially inhibits two delayed rectifier K (+) currents, I (kr) and I (ks), in guinea-pig ventricular myocytes. Br J Pharmacol 1999; 128: 1733-8.
7. Kobayashi S, Reien Y, Ogura T, Saito T, Masuda Y, Nakaya H. In-hibitory effect of bepridil on hKv1.5 channel current: comparison with Amiodarone and E-4031. Eur J Pharmacol 2001; 430: 149-57
8. Kato R, Singh BN. Effects of bepridil on the electrophysiologic properties of isolated canine and rabbit myocardial fibers. Am Heart J 1986; 111: 271-9.
9. Kang L, Zheng MQ, Morishima M, Wang Y, Kaku T, Ono K. Be-pridil up-regulates cardiac Na+ channels as a long-term effect by blunting proteasome signals through inhibition of calmodulin ac-tivity. Br J Pharmacol 2009; 157: 404-14.
10. Nishida K, Fujiki A, Sakamoto T, et al. Bepridil reverses atrial electrical remodeling and L-type calcium channel down-regulation in a canine model of persistent atrial tachycardia. J Cardiovasc Electrophysiol 2007; 18: 765-72.
11. Yasuda M, Nakazato Y, Sasaki A, et al. Clinical evaluation of ad-verse effects during bepridil administration for atrial fibrillation and flutter. Circ J 2006; 70: 662-6.
12. iwano S, Sasaki T, Kurokawa S, et al. Predicting the efficacy of antiarrhythmic agents for interrupting persistent atrial fibrillation according to spectral analysis of the fibrillation waves on the sur-face ECG. Circ J 2009; 73: 1210-8.
13. Niwano S, Wakisaka Y, Kojima J, et al. Monitoring the progres-sion of the atrial electrical remodeling in patients with paroxysmal atrial fibrillation. Circ J 2003; 67: 133-8.
14. Yamashita T, Ogawa S, Sato T, et al. Dose-response effects of be-pridil in patients with persistent atrial fibrillation monitored with transtelephonic electrocardiograms: a multicenter, randomized, placebo-controlled, double-blind study (J-BAF Study). Circ J 2009; 73: 1020-7.
15. Nobe S, Aomine M, Arita M. Bepridil prolongs the action poten- tial duration of guinea pig ventricular muscle only at rapid rates of stimulation. Gen Pharmacol 1993; 24: 1187-96.
16. Chouabe C, Drici MD, Romey G, Barhanin J, Lazdunski M. HERG and KvLQT1/IsK, the cardiac K+ channels involved in long QT syndromes, are targets for calcium channel blockers. Mol Pharmacol 1998; 54: 695-703.
17. Yoshida T, Niwano S, Inuo K, et al. Bepridil prevents paroxysmal atrial fibrillation by a class III antiarrhythmic drug effect. Pacing Clin Electrophysiol 2003; 26: 314-7.
18. Niwano S, Ortiz J, Abe H, Gonzalez X, Rudy Y, Waldo AL. Char- acterization of the excitable gap in a functionally determined reen- trant circuit. Studies in the sterile pericarditis model of atrial flut- ter. Circulation 1994; 90: 1997-2014.
19. Honjo H, Yamazaki M, Kamiya K, Kodama I. Modulation of spi- ral wave reentry by K+ channel blockade. Circ J 2007; 71: A26-31.
20. Yamazaki M, Honjo H, Nakagawa H, et al. Mechanisms of desta- bilization and early termination of spiral wave reentry in the ven- tricle by class III antiarrhythmic agent, nifekalant. Am J Physiol Heart Circ Physiol 2007; 292: H539-48.
21. Wijffels MC, Dorland R, Allessie MA. Pharmacologic cardiover- sion of chronic atrial fibrillation in the goat by class IA, IC, and III drugs: a comparison between hydroquinidine, cibenzoline, flecai- nide, and d-sotalol. J Cardiovasc Electrophysiol 1999; 10: 178-93.
22. Wijffels MC, Dorland R, Mast F, Allessie MA. Widening of the excitable gap during pharmacological cardioversion of atrial fibril- lation in the goat: effects of cibenzoline, hydroquinidine, flecain- ide, and d-sotalol. Circulation 2000; 102: 260-7.
23. Fujiki A, Nagasawa H, Sakabe M, et al. Spectral characteristics of human atrial fibrillation waves of the right atrial free wall with re- spect to the duration of atrial fibrillation and effect of class I an- tiarrhythmic drugs. Jpn Circ J 2001; 65: 1047-51.
24. Sasaki T, Niwano S, Sasaki S, et al. Long-term follow-up of changes in fibrillation waves in patients with persistent atrial fibril-lation: spectral analysis of surface ECG. Circ J 2006; 70: 169-73.
25. Fujiki A, Sakabe M, Nishida K, et al. Drug-induced changes in fi-brillation cycle length and organization index can predict chemical cardioversion of long-lasting atrial fibrillation with bepridil alone or in combination with aprindine. Circ J 2004; 68: 1139-45.
26. Kurita T, Yasuda M, Nakazato Y, et al. Proarrhythmia of bepridil. Jpn J Electrocardiol 2007; 27: 61-73. (Japanese)